In this paper the historical and scientific background that led to the use of substituted benzamides in two apparently unrelated clinical conditions namely dysthymic disorder and schizophrenia will be reviewed, in order to understand if a common mechanism of action may support this dual therapeutic indication. The dopaminergic antidepressant action of substituted benzamides such as sulpiride, has been proposed, since the late 1970s, by several authors and extensively explored in preclinical experiments by our group. In Italy the first marketing authorization obtained for the new substituted benzamide amisulpride, was with the sole indication of dysthymia and therefore a solid clinical experience exists in the use of substituted benzamides in mild forms of depression, with more than 1 000 000 patients being treated in the last 7 years. The proposed mechanism of action of substituted benzamides implies a selective modulation of the dopaminergic system in the mesocorticolimbic area, important for cognitive processing of internal and external cues, related to survival. The selective antagonism of dopamine D2-D3 receptors has been evoked to explain, in small to moderate doses (ie 50-100 mg day −1 ), the antidepressant effect and, in moderate to medium doses (100-400 mg day −1 ), the reported efficacy on negative symptoms of schizophrenia. Thus, substituted benzamides could represent the first class of atypical antipsychotics successfully employed for both depressive states and schizophrenia. Interestingly, recent evidence in the literature suggests that depressive episodes belonging to the bipolar spectrum are among 'alternative indications' of other atypical antipsychotics such as olanzapine and risperidone.
Introduction
Between 1954 and 1975, about forty antipsychotic drugs were introduced throughout the world. Thereafter, there was a hiatus in the development of antipsychotics until the re-introduction of clozapine in the United States in 1990 reopening the era of 'atypical' antipsychotics. 1 Among the various criteria used to label an antipsychotic as atypical a consensus has emerged among clinicians that led to the definition of at least two fundamental parameters: (1) decreased (or non-existent) capacity to cause acute extrapyramidal motor side effects (acute EPS) and tardive dyskinesia (TD); (2) increased therapeutic efficacy reflected by improvement in positive, negative, or cognitive symptoms. 2 If only these two criteria were to be applied, then atypicals were already present since the early 1970s, when clozapine and most substituted benzamides were on the market. If instead three additional criteria, with less consensus in the literature-such as a decreased, or non-existent, capacity to induce hyperprolactinemia, 3 weight gain 4, 5 and better effectiveness in some patients previously regarded as treatment-refractory 6 would be stringently added as essential features in the atypical profile of an antipsychotic, then most of the 'new' antipsychotics could not be considered atypicals.
In the search for new atypicals, the attempt to match the unique therapeutic profile of clozapine has been rooted in three notions which have been utilized to explain its distinction with respect to classical neuroleptics: (1) dose-response separation between particular pharmacological functions; (2) anatomic specificity of particular pharmacological activities; (3) neurotransmitter receptor interactions and pharmacodynamics. 2 As a consequence of this conceptual framework atypicals were generated by two 'schools of thought': the first one leading to designing drugs similar to clozapine (the low antidopaminergic approach) without the danger of the hematological side effects; the other aiming at synthesizing selective dopamine (DA) receptor antagonists based on the findings on benzamides which had shown a peculiar property, ie the large gap between the dose needed to antagonize the central effect of apomorphine or amphetamine and that necessary to produce catalepsy in rodents (the selective DA receptors approach). 7 It must be stressed that these conceptual bases are not mutually exclusive and that, in addition, areas of common functions between different atypical as well as first generation antipsychotics have been considered instrumental to our identification of shared pathophysiological dimensions of schizophrenia, including negative symptoms, and depression. 8 For instance, different depressive states, irrespective of their diagnostic categorization, share in common the incapacity to anticipate, seek and consume 'pleasures' (ie conditions that produce reward) and a decreased cognitive ability to properly perform in everyday life, suggesting a possible common neurobiological basis between 'emotions' and cognition.
Accordingly to the above model, strong experimental evidence has shown that the functions that are controlled by the mesocorticolimbic DA system are impaired in depressive disorders of a different nature, and whenever symptoms of depression can be mimicked in experimental animals they appear to be sustained by a deficit in mesocorticolimbic DA transmission. Thus, a deficit in mesocorticolimbic DA transmission may represent the common neurobiological substrate of the core symptomatology in different depressive conditions independently of their nosological classification, including dysthymic disorder, major depressive disorder, drug-induced depression and, possibly, negative symptoms of schizophrenia. 9 The dopaminergic antidepressant action of compounds belonging to the substituted benzamides family-such as sulpiride-has been proposed by several groups [10] [11] [12] since the late 1970s, and extensively explored in Italy by our group. [13] [14] [15] It is not surprising therefore that, in this country, the first marketing authorization obtained for the new substituted benzamide amisulpride, was with the sole indication of dysthymia. In Italy, there is solid clinical experience in the use of amisulpride in mild forms of depression, with more than 1 000 000 patients being treated to date. 16 The proposed mechanism of action of substituted benzamides implies a selective modulation of the dopaminergic system in the mesocorticolimbic area, which has been called forth to explain the antidepressive effect, 17, 18 in small to moderate doses, including in patients suffering from endogenous depression, 11, 19 or autism 20 and, in moderate to medium doses, a reported efficacy on negative symptoms of schizophrenia, [21] [22] [23] with relatively few extrapyramidal side effects. 24 Thus, substituted benzamides have been the first class of atypical antipsychotics successfully employed for both schizophrenia and depression. Interestingly, there is a growing evidence in the literature to suggest that depressive episodes belonging to the bipolar spectrum are among 'alternative indications' of other atypical antipsychotics. 25 It must said that some of these 'other indications' of antipsychotics were already proposed in the early 1980s. 26, 27 In order to understand whether the proposed selective mechanism of action on the dopaminergic system may underlay a dual therapeutic indication and in the attempt to draw the scientific community attention to the possibility that a different daily dosage of the same compound might treat distant psychopathological conditions, we will review the historical and scientific background that led to the rationale behind the use of substituted benzamides in two otherwise apparently unrelated clinical conditions, namely dysthymic disorder and schizophrenia.
Dopamine, depression and schizophrenia
Almost fifty years of research (reviewed in Carlsson 28 ) have implicated DA both in depressive states and in schizophrenia. In particular, numerous experimental evidence converges to suggest the crucial role of mesocorticolimbic DA in the neurobiological response to rewarding stimuli, 29, 30 and to sensory-specific cues, 31, 32 considered to be linked to incentive salience 33 and/or to associative learning, 34 which has been speculated to be impaired in depressive states of different nature. 35 The finding that reserpine produced depression by reducing the brain content of biogenic amines allowed the original formulation of the hypotheses about the role of monoamines, and particularly DA, in mood regulation and in the action of antidepressant drugs, which has been recently reviewed elsewhere. 36, 37 . Abnormalities in DA neurotransmission have also long been thought to play a role in the pathophysiology of schizophrenia, 38, 39 although more recently the nature of these abnormalities has been the subject of substantial debate. Recently PET data have shown that the synthesis, [40] [41] [42] and the basal 43 as well as the amphetamine-induced [44] [45] [46] release of DA is increased in drug-naive schizophrenic patients, compared with age-matched controls.
Recent formulations of the DA hypothesis of schizophrenia posit that the psychotic symptoms of this disorder reflect a hyperdopaminergic state in subcortical structures, whereas negative/depressive symptoms and the cognitive deficits have been attributed to a hypodopaminergic state in certain cortical association regions, such as the prefrontal (PFC) and entorhinal cortices. [47] [48] [49] Pharmacological evidence sustains the first part of this hypothesis: compounds that increase brain DA levels precipitate or exacerbate positive symptoms such as hallucinations and delusions and secondly, all hitherto discovered antipsychotic drugs have been found to antagonize central DA neurotransmission. 50, 51 . This last point is difficult to reconcile with the fact that the negative symptoms of schizophrenia are instead worsened by a decreased DA activity in the PFC. 52, 53 This apparent contradiction between high or low DA activity has been addressed by recent evidence from model systems suggesting that reduced DA modulation of neuronal activity in the PFC can contribute to excessive DA activity in the subcortical areas. 54 Accordingly, increasing the DA output in the PFC would have the dual therapeutic action of improving the negative symptomatology and, consequently, the positive one, by decreasing mesolimbic DA activity. Again, support for this hypothesis has come from the clinical efficacy of the atypical antipsychotic clozapine which, despite a lower D 2 receptor occupancy in brain (that is, 45-50%), 55 has remarkable therapeutic actions on both the positive and the negative symptoms of schizophrenia, 56 and, in contrast to classical neuroleptics, induces a marked increase in the DA output of the PFC. 57, 58 Clozapine's superior efficacy is thought to be based on its ability to influence the function of a broad spectrum of neurotransmitter systems; in addition to its antagonism on DA receptors, clozapine is a potent antagonist of noradrenergic, serotonergic, muscarinic and histaminic binding sites. 59 A different approach is that provided by substituted benzamides, starting from sulpiride, (available for clinical use since 1967 60 ) to the more recent amisulpride, 61 which share the ability to putatively block a different subclass of dopaminergic receptors. Owing to this differential action, the clinical use of substituted benzamides 60 ranges from that of major neuroleptics, as in the case of sultopride and tiapride, to a tymoleptic-like, antidepressant and non sedative action, as in the case of sulpiride 62 and amisulpride, 63, 64 albeit at much lower dose. 65 In addition, these drugs increase brain DA synthesis 66 and turnover in DA terminal areas as demonstrated by an increased concentration of homovanillic acid in the brain of rodents 67 and humans. 68 Sulpiride is the oldest member of the substituted benzamides class while amisulpride is the clinically most established. Their detailed pharmacodynamics are reported elsewhere. 69, 70 Remoxipride and raclopride are two other recently described members of this class. They are also selective D2 receptor blockers with preferential action in mesolimbic areas 71 and their clinical efficacy has been evaluated in several studies [72] [73] [74] [75] in which they showed an antipsychotic efficacy comparable to that of traditional neuroleptics, demonstrating that the selective dopaminergic approach has consistently produced compounds that are currently employed in the clinical treatment of schizophrenia.
Modulation of the dopaminergic system: a common therapeutic target for both depression and schizophrenia?
Several findings suggest that the reduction of DA transmission might be produced via different mechanisms. Long-term exposure of rats to mild stress causes a decreased sensitivity to reward, which has been suggested as being homologous to anhedonia, a specific trait of both depression and negative symptoms of schizophrenia. This behavioral effect in rats is associated with a decreased responsiveness of D 2 /D 3 DA receptors in the nucleus accumbens. Both the behavioral response and the decreased sensitivity of DA receptors are reversed by chronic treatment with Molecular Psychiatry classic or new antidepressants 76 and by the substituted benzamides amisulpride, 77 raclopride and sulpiride. 78 In the mild stress-induced model, postsynaptic DA receptors are hyposensitive while DA release is not reduced, while in the psychostimulant-withdrawal model there is an inhibition of DA output associated with supersensitivity of postsynaptic DA receptors. Thus, experimental data would suggest that the sole impairment of dopaminergic transmission could not be regarded as essential for producing a depressive status in the animal. The presence of hyper or hyposensitivity of postsynaptic DA receptors might explain the presence or absence of psychotic symptoms, such as delusions and agitation, in different depressive disorders (ie mixed states) or in the recurrences of schizophrenic episodes. The therapeutic implication of such differences is that some episodes with psychotic features may be worsened by antidepressant treatments that increase the monoamine concentration rather than selectively modulate the dopaminergic tone in the mesocorticolimbic system. Interestingly, the strategy of dopaminergic stabilization has been recently proposed as a promising novel therapeutic approach in schizophrenia, 79 by employing a series of compounds capable of modulating the dopaminergic system, without inducing the hypodopaminergia so common for most antipsychotics available to date. Some of these new drugs, belonging to the dopamine D2 receptor family partial agonists are now undergoing clinical trials. 80 Others, such as phenyl-piperidines and benzamides, are pure antagonists acting on the same D2 family of receptors, and thought to readjust elevated dopamine levels without producing hypodopaminergia. The reason for this aberrant pharmacological profile seems to be that they act on subpopulations of dopamine receptors in a manner different from that of the currently used drugs. 79, 80 They either exert a strong action on dopaminergic autoreceptors and/or they have a weaker effect postsynaptically, and/or they seem unable to reach a subpopulation of postsynaptic dopamine receptors. 81, 82 The clinical significance of modulating, rather than simply decreasing or increasing DA transmission in the PFC, stems from the fact that cognitive symptoms have been associated with the finding that DA levels in the PFC should be maintained in a precise range in order to avoid functional impairment (see below). This has been shown in numerous diseases other than depression 83 or schizophrenia; 84 including Huntington's, 85 drug addiction, 86 and Parkinson's 87 as well as in normal aging. 88 A variety of experimental and neuropsychological studies suggest a direct association between 'unmodulated' dopamine transmission in the PFC and cognitive deficits. [89] [90] [91] Should atypical antipsychotics be able to 'modulate' rather than impair PFC dopaminergic transmission?
Beyond 'neuronal and dopaminergic' dopamine
We have recently shown that the dopaminergic output in the rat PFC could be an expression of the activity of noradrenergic neurons as well. 92 Atypical antipsychotics by blocking DA autoreceptors localized on noradrenergic neurons would increase DA and NE output not only from DA neurons but from noradrenergic neurons where these two monoamines may act as cotransmitters. In the same area approximately 35% of the total D2 ligand binding activity is known to be associated with astrocytes isolated from rodents (mice and rats) and primates (monkeys and humans), while astrocytes isolated from D2 receptor knock-out mice failed to show any D2-ligand binding. 93 The functional nature of these receptors is sustained-directly-by the fact that a 25% increase in intracellular Ca 2+ is induced after the local application of the D2-receptor-specific agonist quinpirole, an effect reversibly blocked by the substituted benzamide raclopride; and-indirectly-by the observation that chronic treatment with D2-antagonist drugs tend to alter the density of glial cells in the PFC of rhesus monkey, 94 suggesting the existence of a constant dopaminergic tone at the level of the PFC glial network.
Since the electron microscopic analysis showed that D2 receptors in the astrocytes make close anatomical association with interneurons in the cerebral cortex, this suggests not only that this association might provide a substrate for the functional interaction between the two cell types, but it may also imply that some of the differences between typical and atypical neuroleptic drugs with respect to relief of clinical symptoms or production of side-effects might account for therapeutic actions at glial targets.
The exact nature of these receptors, whether belonging to the D2Long (D2L) or the D2Short (D2S) isoforms, 95 must be ascertained, since they can represent an important pharmacological target for the action of selective dopaminergic atypical antipsychotics of the benzamides class, as has been proposed for remoxipride. 96 If these recent data are confirmed, then the proposed selective affinity of benzamides such as sulpiride, remoxipride, raclopride and amisulpride 97 for this subtype of DA receptor should be evaluated in order to better characterize their atypical profiles. The heuristic value in the discovery of different isoforms and different cellular localization of the D2 receptor is supported by reports which show that antipsychotic drugs which elicit Parkinsonism (trifluperazine, chlorpromazine, raclopride, haloperidol, fluphenazine) bind more tightly than dopamine to D2, while those antipsychotic drugs which elicit little or no Parkinsonism (melperone, quetiapine, clozapine, remoxipride, amisulpride, olanzapine, sertindole) bind more loosely than dopamine to D2 receptors, 98 irrespective of their chemical structure (ie raclopride and amisulpride are both benzamides) and, perhaps more importantly, independently from the absolute levels of dopamine D2 receptors occupancy. The question arises whether the cataleptic propensity of atypical antipsychotics might be ascribed to their preferential affinity for one or the other of the DA D2 isoforms and/or for the D2 localized on non-dopaminergic and/or non-neuronal (glia) cells.
The role of dopamine D1 receptors
To complicate further the understanding of these circuits, one should bear in mind that when the PFC distribution of DA receptors is studied, then the D1 family of dopamine receptors is at least 20-fold more abundant than the D2 family of receptors in this area. 99, 100 The functional effect of dopaminergic neurotransmission in cortical circuits is not yet fully understood, but the role of the DA D1 receptor has received a great deal of attention, thanks to the seminal work of the group led by Patricia Goldman-Rakic. These authors have shown that the tuning of PFC neurons engaged in cognitive tasks is enhanced at moderate levels of D1 occupancy and reduced at both lower and higher levels of occupancy. These findings may be relevant to both normal functioning and clinical conditions. It is of interest that a recent PET study has revealed that the D1 receptor is decreased in the PFC of both medicated and nonmedicated schizophrenic patients. In addition, the density of D1 receptors was positively correlated with performance of the patients on the Wisconsin Card Sorting Task. 101 Normal aging also brings with it a decline in dopamine levels and D1 receptor function 102, 103 and in working memory. 104 Given the vulnerability of cognitive functions to DA dysfunction, 105 it would not be surprising if a common pathophysiological process would be responsible both for cognitive processes in normal individuals, in schizophrenic and in depressed individuals with prominent cognitive deficits. 106 It appears therefore important that, in the action of an antipsychotic (and perhaps of an antidepressant), a selective blockade of DA D2 family receptors is preferred over an indiscriminate D1/D2 receptors blockade. An antagonism at the level of the DA D2 autoreceptor in the PFC, by increasing the DA output and DA action on D1 receptors, could ameliorate the cognitive/negative symptomatology.
Conclusions
Symptoms of both schizophrenia and depression involve a reduction or absence of normal thoughts, emotions, and behavior. Negative symptoms of schizophrenia, such as flatten affect, alogia, or avolition (A5 criteria), 107 have significant overlaps with the clinical presentation of depressive disorders such as dysthymia. In dysthymia, negative symptomatology will be present with variable levels of hedonic impairment, as in the melancholic type (eg finding no pleasure in doing any or almost any activities); cognitive impairment (eg finding it difficult to concentrate and make decisions); or lack of drive and will (eg demonstrating low levels of energy or fatigue). In all cases, these types of symptoms would produce clinically significant distress or impairment in work, social, or other areas of important functioning. The literature indicates that emotional-cognitive symptoms are much more charac-teristic of dysthymia than the vegetative and psychomotor symptoms of major depression, and recently two multicenter collaborative trials found that dysthymic disorder appears to primarily involve psychologic symptoms that seem to cluster into affective vs cognitive deficits. 108 Dysthymia proper, dominated by negative affectivity, might be distinguishable from a 'neurasthenic' subform dominated by low energy or 'deficit' symptoms at mental and physical levels. 109 On the other hand, anhedonic symptoms in schizophrenia belong to the associated features of the disorder and, along with classical negative symptoms, are difficult to distinguish from the alogia, blunted affect or avolition of a dysthymic individual.
Since the monoamine hypothesis of depression predicted an impairment in central monoaminergic function, such deficiencies were thought to be reflected in the absolute concentrations of monoamines. Until now, measurement of the concentrations of the neurotransmitters and their metabolites in cerebrospinal fluid, urine, and plasma of patients with depression has yielded equivocal results regarding the possibility of altered metabolism of these neurotransmitters and the development of sensitive markers of endogenous depression. 110 However, very recently, using catheters placed in an internal jugular vein, the release of brain monoamine neurotransmitters was estimated, at rest and following intravenous desipramine hydrochloride, in healthy volunteers and in patients with unipolar depressive illness refractory to medication. Surprisingly, while both the reduction in NE turnover and the defect in cerebral metabolism were normalized following pharmacological blockade of the NE transporter with desipramine, it was the brain's turnover of DA that bore a significant relation to the patients' clinical status. 111 We have here argued that the proposed, albeit debated, 112 selective mechanism of action of the atypical antipsychotics belonging to the substituted benzamides class might sustain the possibility that a different daily dosage of the same compound might treat distant psychopathological conditions such as dysthymia and schizophrenia A better understanding of how the DA system may be affected by external or internal stimuli-which usually precipitate affective or psychotic episodes-or by drugs employed to treat such episodes, may offer not only a simplification of the nosological heterogeneity of the different depressive states, but would also offer a reasonable explanation for why certain second generation antipsychotics may be successfully employed in both the depressive symptoms and signs which present themselves in the context of a depressive or a schizophrenic cluster of mental disorders.
